糖耐量减低的药物干预

Pharmacological intervention of IGT

我国成年糖尿病前期患病人群庞大,且以IGT患者为主。IGT不仅是T2DM的高危因素,还与糖尿病微血管并发症及大血管并发症密切相关。干预IGT,阻止或延缓其发展为糖尿病已成为当务之急。当单纯生活方式干预无法达到预期的糖尿病预防目标时,应考虑采用药物进行治疗。本文将对IGT的病理生理机制、IGT药物干预的有效性、安全性及药物经济学作一综述。

There is a huge population of adults with pre-diabetes in China,and the majority of whom are impaired glucose tolerance（IGT）patients.IGT is not only a risk factor for type 2 diabetes,but is also closely related to diabetic microvascular and macrovascular complications.Preventing or delaying the development of diabetes by intervention on IGT has become imperative.When lifestyle intervention alone cannot achieve the ideal goal of diabetes prevention,pharmacological intervention should be considered.This review will discuss thepathophysiology of IGT,and the effectiveness,safety and pharmacoeconomics of IGT pharmacological intervention.